Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

BACKGROUND: Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). Preliminary data suggest that interventions lowering gastro-intestinal phosphate uptake lowers serum FGF23...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nephron Clin Pract
Prif Awduron: Adema, Aaltje Y., de Jong, Maarten A., de Borst, Martin H., ter Wee, Pieter M., Vervloet, Marc G.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: S. Karger AG 2016
Pynciau:
Clinical Practice: Original Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5296888/
https://ncbi.nlm.nih.gov/pubmed/27442253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000448184
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg